ARTICLEhttps://harbor.dev.pubfactory.com/view/journals/jnccn/17/5/article-p432.xmlA Population-Based Study of Morbidity After Pancreatic Cancer Diagnosis2019-11-21https://harbor.dev.pubfactory.com/view/journals/jnccn/17/5/article-p432.pdf2020-12-01A Population-Based Study of Morbidity After Pancreatic Cancer Diagnosishttps://harbor.dev.pubfactory.com/view/journals/jnccn/17/5/article-p441.xmlIs Primary Androgen Deprivation Therapy a Suitable Option for Asian Patients With Prostate Cancer Compared With Radical Prostatectomy?2019-11-21https://harbor.dev.pubfactory.com/view/journals/jnccn/17/5/article-p441.pdf2020-12-01Is Primary Androgen Deprivation Therapy a Suitable Option for Asian Patients With Prostate Cancer Compared With Radical Prostatectomy?https://harbor.dev.pubfactory.com/view/journals/jnccn/17/5/article-p450.xmlStereotactic Body Radiation Therapy Versus Nonradiotherapeutic Ablative Procedures (Laser/Cryoablation and Electrocautery) for Early-Stage Non–Small Cell Lung Cancer2019-11-21https://harbor.dev.pubfactory.com/view/journals/jnccn/17/5/article-p450.pdf2020-12-01Stereotactic Body Radiation Therapy Versus Nonradiotherapeutic Ablative Procedures (Laser/Cryoablation and Electrocautery) for Early-Stage Non–Small Cell Lung Cancerhttps://harbor.dev.pubfactory.com/view/journals/jnccn/17/5/article-p459.xmlAdverse Health Outcomes in Relationship to Hypogonadism After Chemotherapy: A Multicenter Study of Testicular Cancer Survivors2019-11-21https://harbor.dev.pubfactory.com/view/journals/jnccn/17/5/article-p459.pdf2020-12-01Adverse Health Outcomes in Relationship to Hypogonadism After Chemotherapy: A Multicenter Study of Testicular Cancer Survivorshttps://harbor.dev.pubfactory.com/view/journals/jnccn/17/5/article-p409.xml KRAS G12V Mutation in Acquired Resistance to Combined BRAF and MEK Inhibition in Papillary Thyroid Cancer2019-11-21https://harbor.dev.pubfactory.com/view/journals/jnccn/17/5/article-p409.pdf2020-12-01 KRAS G12V Mutation in Acquired Resistance to Combined BRAF and MEK Inhibition in Papillary Thyroid Cancerhttps://harbor.dev.pubfactory.com/view/journals/jnccn/17/5/article-p469.xmlComparative Effectiveness of Carboplatin/Pemetrexed With Versus Without Bevacizumab for Advanced Nonsquamous Non–Small Cell Lung Cancer2019-11-21https://harbor.dev.pubfactory.com/view/journals/jnccn/17/5/article-p469.pdf2020-12-01Comparative Effectiveness of Carboplatin/Pemetrexed With Versus Without Bevacizumab for Advanced Nonsquamous Non–Small Cell Lung Cancerhttps://harbor.dev.pubfactory.com/view/journals/jnccn/17/5/article-p506.xmlCurrent Status of MRI and PET in the NCCN Guidelines for Prostate Cancer2019-11-21https://harbor.dev.pubfactory.com/view/journals/jnccn/17/5/article-p506.pdf2020-12-01Current Status of MRI and PET in the NCCN Guidelines for Prostate Cancerhttps://harbor.dev.pubfactory.com/view/journals/jnccn/17/5/article-p515.xmlGermline and Somatic Mutations in Prostate Cancer for the Clinician2019-11-21https://harbor.dev.pubfactory.com/view/journals/jnccn/17/5/article-p515.pdf2020-12-01Germline and Somatic Mutations in Prostate Cancer for the Clinicianhttps://harbor.dev.pubfactory.com/view/journals/jnccn/17/5/article-p424.xmlPolicy Challenges and Opportunities to Address Changing Paradigms in Cancer Care Delivery2019-11-21https://harbor.dev.pubfactory.com/view/journals/jnccn/17/5/article-p424.pdf2020-12-01Policy Challenges and Opportunities to Address Changing Paradigms in Cancer Care Deliveryhttps://harbor.dev.pubfactory.com/view/journals/jnccn/17/5/article-p523.xmlPrimary Androgen Deprivation Therapy for Nonmetastatic Prostate Cancer in Asia: Unique or Not?2019-11-21https://harbor.dev.pubfactory.com/view/journals/jnccn/17/5/article-p523.pdf2020-12-01Primary Androgen Deprivation Therapy for Nonmetastatic Prostate Cancer in Asia: Unique or Not?https://harbor.dev.pubfactory.com/view/journals/jnccn/17/5/article-p479.xmlProstate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology2019-11-21https://harbor.dev.pubfactory.com/view/journals/jnccn/17/5/article-p479.pdf2020-12-01Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncologyhttps://harbor.dev.pubfactory.com/view/journals/jnccn/17/5/article-p414.xmlNCCN Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.20192019-11-21https://harbor.dev.pubfactory.com/view/journals/jnccn/17/5/article-p414.pdf2020-12-01NCCN Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2019https://harbor.dev.pubfactory.com/view/journals/jnccn/17/5/article-pxxiv.xmlNCCN News2019-11-21https://harbor.dev.pubfactory.com/view/journals/jnccn/17/5/article-pxxiv.pdf2020-12-01NCCN Newshttps://harbor.dev.pubfactory.com/view/journals/jnccn/17/5/article-pxxii.xmlOncology Research Program2019-11-21https://harbor.dev.pubfactory.com/view/journals/jnccn/17/5/article-pxxii.pdf2020-12-01Oncology Research Programhttps://harbor.dev.pubfactory.com/view/journals/jnccn/17/5/article-p407.xmlFinding Room for Success2019-11-21https://harbor.dev.pubfactory.com/view/journals/jnccn/17/5/article-p407.pdf2020-12-01Finding Room for Success